BioCorRx Provides Business Update for the First Quarter of 2023
Revenue Increases 97%
ANAHEIM, CA, May 16, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended March 31, 2023 and reported on recent corporate developments.
Related news for (BICX)
- BioCorRx Reports Business Update for the Second Quarter of 2024
- BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
- BioCorRx Reports Business Update for 2023
- BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
- BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors